Lisa N. Colleran
Known title: DirectorCIK: 0001212312
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ESTA Receives FDA Approval for New Motiva Implant Sizes. Establishment Labs Holdings received FDA clearance for additional sizes of its Motiva implants, expanding its product lineup. The company also reported its Q2 2026 financial results. This regulatory approval is a key development for the medical device maker, potentially broadening its market reach.
Transaction History
| TELA | ▲ Buy | Grant | 7,950 | $0 | 5/28/2025 | View on chart |
| TELA | ▲ Buy | Grant | 4,250 | $0 | 6/4/2024 | View on chart |
| TELA | ▲ Buy | Grant | 3,135 | $0 | 6/1/2023 | View on chart |
| ESTA | ▲ Buy | Grant | 2,345 | $0 | 6/17/2022 | View on chart |
| TELA | ▲ Buy | Grant | 3,135 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Craig-Hallum initiates coverage on TELA Bio with $2 target
Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.
Craig-Hallum initiates coverage on TELA Bio with $2 target. Craig-Hallum has started tracking TELA Bio, assigning a price target of $2. This new analyst note aligns with the current average analyst target of $2.08. The stock is currently trading above its 52-week low of $0.50, with recent technical indicators showing momentum near the upper end of its recent range.